PMID- 21386634
OWN - NLM
STAT- MEDLINE
DCOM- 20110809
LR  - 20181201
IS  - 1590-8577 (Electronic)
IS  - 1590-8577 (Linking)
VI  - 12
IP  - 2
DP  - 2011 Mar 9
TI  - Pancreatic neuroendocrine tumors: role of novel agents. Highlights from the "2011 
      ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 
      2011.
PG  - 117-9
AB  - Neuroendocrine tumors of pancreas (PNET) are very rare, consisting of 
      heterogeneous histological subtypes with a variable natural history and different 
      clinical manifestations. Although the vast majority of these neoplasms are 
      sporadic, it is possible to be part of a genetic syndrome such as multiple 
      endocrine neoplasia 1 (MEN-1) or tuberous sclerosis (TSC). When systemic 
      treatment is required the options are limited and management strategy is 
      generally based on experts' consensus or clinical experience. The prognosis is 
      usually better than in pancreatic adenocarcinoma, though poorly differentiated 
      PNET behave aggressively and survival is shortened. Since last year, there has 
      been a significant advance in the management of PNET, after reported data 
      confirmed the efficacy of everolimus, an mTOR inhibitor, in patients with 
      advanced disease. At the 2011 American Society of Clinical Oncology (ASCO) 
      Gastrointestinal Symposium, updated results of the phase III trial (RADIANT-3) 
      regarding the efficacy of everolimus in PNET (Abstract #158) were reported, along 
      with the results of a subgroup analysis of the Japanese patients enrolled in this 
      study (Abstract #289). Another agent with promising activity in PNET which will 
      be discussed in this review is sunitinib, a biological agent with multikinase 
      inhibitor properties (Abstract #244).
FAU - Strimpakos, Alexios S
AU  - Strimpakos AS
AD  - Oncology Unit, Third Department of Medicine, University of Athens, Sotiria 
      General Hospital. Athens, Greece.
FAU - Syrigos, Konstantinos N
AU  - Syrigos KN
FAU - Saif, Muhammad Wasif
AU  - Saif MW
LA  - eng
PT  - Congress
DEP - 20110309
PL  - England
TA  - JOP
JT  - JOP : Journal of the pancreas
JID - 101091810
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Immunosuppressive Agents)
RN  - 0 (Indoles)
RN  - 0 (Pyrroles)
RN  - 9HW64Q8G6G (Everolimus)
RN  - V99T50803M (Sunitinib)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - Clinical Trials, Phase III as Topic
MH  - Everolimus
MH  - Humans
MH  - Immunosuppressive Agents/therapeutic use
MH  - Indoles/therapeutic use
MH  - Neuroendocrine Tumors/*drug therapy/pathology
MH  - Pancreatic Neoplasms/*drug therapy/pathology
MH  - Pyrroles/therapeutic use
MH  - Sirolimus/*analogs & derivatives/therapeutic use
MH  - Sunitinib
MH  - Treatment Outcome
EDAT- 2011/03/10 06:00
MHDA- 2011/08/10 06:00
CRDT- 2011/03/10 06:00
PHST- 2011/03/10 06:00 [entrez]
PHST- 2011/03/10 06:00 [pubmed]
PHST- 2011/08/10 06:00 [medline]
AID - v12i02a10 [pii]
PST - epublish
SO  - JOP. 2011 Mar 9;12(2):117-9.